Filing Flows › Health Care › Assembly Biosciences (ASMB)
Assembly Biosciences (ASMB) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · Assembly Biosciences (ASMB) Q2 2026 earnings results →
Q2 2026 Revenue up 39% year over year to $13.4M · 29¢ of every $1 of revenue lost · operating margin -47.4%
Assembly Biosciences made $13.4M in Q2 2026 (+39% Y/Y). Operating margin -47.4%, net loss $3.9M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $13.4M in Q2 2026, up 39% year over year and up 63% from the previous quarter.
Operating costs exceeded revenue by $6.3M, an operating margin of -47.4%. Total costs fell 5% while revenue rose 39%. The quarter ended with a net loss of $3.9M, narrower than the previous quarter's $9.1M loss. Non-operating items added $2.5M, -64% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$15.5M. Non-cash charges added back $20K of depreciation and amortization and $2.4M of share-based compensation. Working capital and other items used $14.1M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $13.4M | +39% | -47.4% | −$3.9M | −$15.5M |
| Q1 2026 | 10-Q | May 7, 2026 | $8.2M | -13% | -138.4% | −$9.1M | −$22.1M |
| Q3 2025 | 10-Q | Nov 10, 2025 | $10.8M | +58% | -100.9% | −$9.2M | −$15.1M |
| Q2 2025 | 10-Q | Aug 6, 2025 | $9.6M | +13% | -115.2% | −$10.2M | −$16.8M |
| Q1 2025 | 10-Q | May 8, 2025 | $9.4M | +63% | -105.5% | −$8.8M | −$23.4M |
| Q4 2024 | 10-K | Mar 20, 2025 | $7.4M | +3% | -156.7% | −$10.3M | −$407K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Assembly Biosciences
We are a biotechnology company developing innovative therapeutics targeting serious viral diseases with the potential to improve the lives of patients worldwide. Our pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPIs) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus (HDV) entry inhibitor; and (3) a highly potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Our pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses, which is currently undergoing studies to enable a regulatory filing, and we have additional research programs against multiple antiviral targets.
In its own words, from its 10-K, filed Mar 19, 2026.
Assembly Biosciences against its Pharmaceutical Preparations peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +39% against the peers' median +10%. Operating margin: -47.4% against the peers' median 20.4%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| ASMB Assembly Biosciences | Q2 2026 | $13.4M | +39% | -47.4% |
| JNJ Johnson & Johnson | Q3 2026 | $25.4B | +6% | 0.1% |
| LLY ELI Lilly | Q3 2026 | $24.4B | +39% | 34.5% |
| MRK Merck | Q3 2026 | $18.1B | +5% | 30.7% |
| ABBV AbbVie | Q3 2026 | $17.4B | +10% | 36.0% |
| PFE Pfizer | Q3 2026 | $16.6B | -0.4% | 20.4% |
| BMY Bristol Myers Squibb | Q3 2026 | $13.1B | +7% | 19.4% |
| ABT Abbott Laboratories | Q3 2026 | $13.0B | +14% | 10.4% |
| REGN Regeneron Pharmaceuticals | Q3 2026 | $5.1B | +36% | 40.0% |
Source: Assembly Biosciences 10-Q on SEC EDGAR · CIK 1426800 · Pharmaceutical Preparations
13F: who owns ASMB and who is buying
More on ASMB
History
Every quarter: Q2 2026 results · Q1 2026 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results